Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Alvocidib Biomarker-driven Phase 2 AML Study

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Alvocidib
Drug: Mitoxantrone

First Posted Date: 2015-08-11

Last Posted Date: 2023-11-15

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 104

Registration Number: NCT02520011

Locations: 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
Morristown Cancer Center, Morristown, New Jersey, United States

and more 35 locations

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Plasma Cell Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Ixazomib Citrate
Drug: Melphalan
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Quality-of-Life Assessment
Drug: Tacrolimus

First Posted Date: 2015-07-21

Last Posted Date: 2020-11-23

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 11

Registration Number: NCT02504359

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

BL-8040 Addition to Consolidation Therapy in AML Patients

Phase 2

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: BL-8040
Drug: Placebo (for BL-8040)

First Posted Date: 2015-07-20

Last Posted Date: 2015-09-21

Lead Sponsor: Dr. Petra Tschanter

Target Recruit Count: 194

Registration Number: NCT02502968

Locations: 🇩🇪
Univeritätsklinikum Halle, Klinik Innere Medizin 4, Halle, Germany

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Bemcentinib
Drug: Cytarabine
Drug: Decitabine

First Posted Date: 2015-07-02

Last Posted Date: 2024-12-19

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 122

Registration Number: NCT02488408

Locations: 🇩🇪
Universitätsklinikum Ulm, Ulm, Germany
🇮🇹
Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
🇩🇪
Medizinische Hochschule Hannover,Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation,, Hannover, Carl-Neuberg-Str, Germany

and more 9 locations

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Phase 1

Completed

Conditions: Granulocytic Sarcoma
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: 6,8-Bis(benzylthio)octanoic Acid
Drug: Cytarabine
Procedure: Hematopoietic Cell Transplantation
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2015-06-29

Last Posted Date: 2024-04-30

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 49

Registration Number: NCT02484391

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Phase 1

Terminated

Conditions: Burkitt Lymphoma
CD20-Positive Neoplastic Cells Present
Indolent Non-Hodgkin Lymphoma
Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Clearing Agent
Drug: Cytarabine
Drug: Etoposide
Radiation: Indium In 111-DOTA-Biotin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Yttrium Y 90-DOTA-Biotin

First Posted Date: 2015-06-26

Last Posted Date: 2020-11-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT02483000

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Phase 1

Conditions: Adult Burkitt Lymphoma
MYC Gene Mutation
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
Plasmablastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Therapeutic Hydrocortisone
Drug: Vincristine Sulfate

First Posted Date: 2015-06-25

Last Posted Date: 2022-02-21

Lead Sponsor: Northwestern University

Target Recruit Count: 38

Registration Number: NCT02481310

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 2 locations

6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: 6,8-Bis(benzylthio)octanoic Acid
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride

First Posted Date: 2015-06-16

Last Posted Date: 2018-07-03

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT02472626

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Nivolumab
Drug: Idarubicin
Drug: Cytarabine
Drug: Solu-medrol
Drug: Dexamethasone

First Posted Date: 2015-06-08

Last Posted Date: 2021-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT02464657

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Genetic: HLA mismatched stem cell
Genetic: HLA matched stem cell
Drug: cyclosporine A
Drug: Ara-C
Drug: Mycophenolate mofetil
Drug: fludarabine
Drug: anti-lymphocyte globulin
Drug: cyclophosphamide

First Posted Date: 2015-06-03

Last Posted Date: 2015-06-04

Lead Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Target Recruit Count: 156

Registration Number: NCT02461121

Locations: 🇨🇳
Affiliated Hospital of Academy of Military Medical Sciences ,, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy